It’s only a benefit if it doesn’t bog the next stage down in noise. At that point it could be detrimental.

We already see that with software. It will be exactly the same with drug design.

My daughter is a leading biochem at one of the big pharma companies and that’s their principal worry about this. It’s really easy to create a lot of information these days which compromises the entire process.